Cara Therapeutics, Inc. (CARA) Price Target Increased to $29.00 by Analysts at CIBC
Cara Therapeutics, Inc. (NASDAQ:CARA) had its target price upped by CIBC from $28.00 to $29.00 in a report issued on Monday, May 15th, StockTargetPrices.com reports.
Other equities research analysts have also issued research reports about the stock. Vetr raised shares of Cara Therapeutics from a sell rating to a strong-buy rating and set a $16.96 price objective on the stock in a research note on Tuesday, January 17th. HC Wainwright boosted their price objective on shares of Cara Therapeutics from $22.00 to $30.00 and gave the stock a buy rating in a research note on Tuesday, March 28th. Canaccord Genuity reissued a buy rating and set a $25.00 price objective on shares of Cara Therapeutics in a research note on Friday, March 10th. Zacks Investment Research lowered shares of Cara Therapeutics from a hold rating to a sell rating in a research note on Tuesday, March 14th. Finally, Piper Jaffray Companies reissued a positive rating and set a $23.00 price objective on shares of Cara Therapeutics in a research note on Tuesday, March 28th. Three analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Cara Therapeutics has an average rating of Buy and a consensus target price of $26.17.
Cara Therapeutics (NASDAQ CARA) remained flat at $17.12 during mid-day trading on Monday. 6,862,360 shares of the stock traded hands. Cara Therapeutics has a 1-year low of $4.35 and a 1-year high of $20.90. The company has a 50-day moving average of $16.60 and a 200 day moving average of $14.71. The stock’s market capitalization is $556.52 million.
Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by $0.08. The business had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $0.11 million. The company’s revenue for the quarter was up 12900.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.39) EPS. Equities analysts predict that Cara Therapeutics will post ($2.37) earnings per share for the current fiscal year.
In related news, major shareholder Ventures Vi Lp Rho bought 500,000 shares of the firm’s stock in a transaction on Friday, March 31st. The shares were bought at an average price of $18.19 per share, with a total value of $9,095,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.70% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN increased its position in shares of Cara Therapeutics by 127.2% in the third quarter. Wells Fargo & Company MN now owns 12,007 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 6,722 shares during the period. Private Advisor Group LLC purchased a new stake in Cara Therapeutics during the fourth quarter valued at $117,000. Quantbot Technologies LP purchased a new stake in Cara Therapeutics during the first quarter valued at $124,000. Flinton Capital Management LLC bought a new stake in shares of Cara Therapeutics during the fourth quarter valued at $139,000. Finally, UBS Group AG increased its stake in shares of Cara Therapeutics by 16.9% in the first quarter. UBS Group AG now owns 10,544 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 1,528 shares in the last quarter. 54.84% of the stock is owned by hedge funds and other institutional investors.
About Cara Therapeutics
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
Receive News & Stock Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related stocks with our FREE daily email newsletter.